Medilax (Lactulose)

Lactulose is an osmotic agent that reaches the colon unchanged, where intestinal bacteria ferment it into short‑chain fatty acids. This process acidifies the colonic environment, drawing water into the lumen to soften stools and stimulate peristalsis. The acidic pH also converts ammonia to ammonium, limiting its absorption and thereby decreasing systemic ammonia concentrations.

The dose of Medilax is individualized by the prescribing healthcare professional based on the patient’s condition, age, and response. Typical regimens start with a low dose that is gradually increased until the desired clinical effect is achieved, but exact amounts and frequency should only be set by a qualified prescriber.

Safety data for lactulose in pregnancy and lactation are limited. It is classified as a Category C medication in many regions, meaning risk cannot be ruled out. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential benefits and risks with their healthcare provider before using Medilax.

To request Medilax, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including any cold‑chain requirements) and assist with import documentation.

Medilax (lactulose) differs from polyethylene glycol‑based laxatives in that it is a disaccharide that is metabolized by colonic bacteria, providing both laxative and ammonia‑lowering effects. Polyethylene glycol acts purely as an osmotic agent without influencing ammonia levels. Choice of therapy depends on the clinical indication—lactulose is preferred when hepatic encephalopathy is a concern, whereas polyethylene glycol may be chosen for simple constipation without liver disease.

Medilax should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the container tightly closed when not in use. Do not freeze the product, and ensure it is kept out of reach of children.

Medilax is taken orally. The product is typically dissolved in a small amount of water or another suitable liquid before ingestion, although it can also be mixed with juice or milk to improve palatability. It should be taken as directed by the prescribing clinician, with or without food, according to the prescribed schedule.

Serious risks include severe dehydration, marked electrolyte disturbances (especially sodium and potassium), and rare allergic reactions such as rash, itching or swelling. Patients experiencing persistent diarrhea, abdominal pain, or signs of dehydration should seek medical attention promptly. Monitoring of fluid and electrolyte status is advisable during prolonged therapy.

Medilax is contraindicated in individuals with known hypersensitivity to lactulose or any of its excipients. It should be used with caution in patients with severe renal impairment, uncontrolled diabetes, or active gastrointestinal obstruction. Children, pregnant or breastfeeding women should only use it after a thorough risk‑benefit assessment by a qualified healthcare professional.